Trevi Therapeutics appoints new CFO
Source: SeekingAlpha
2025-12-04 07:43:18 ET
More on Trevi Therapeutics
- Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond
- Trevi Therapeutics: Big Cough Data, Bigger Execution Risk
- Trevi Therapeutics, Inc. (TRVI) Q3 2025 Earnings Call Transcript
- Trevi Therapeutics edges higher amid takeover speculation
- Trevi Therapeutics targets multiple phase III trial launches for chronic cough indications in 2026 as regulatory plans accelerate
Read the full article on Seeking Alpha
For further details see:
Trevi Therapeutics appoints new CFO
Trevi Therapeutics Inc.
NASDAQ: TRVI
TRVI Trading
-6.92% G/L:
$11.98 Last:
1,074,283 Volume:
$12.86 Open:
TRVI Latest News
March 09, 2026 07:30:00 am
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough
February 17, 2026 07:30:00 am
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
TRVI Stock Data
$1,448,359,364
104,764,019
0.7%
59
N/A
Biotechnology & Life Sciences
Healthcare
US
New Haven
